Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 167

1.

Increased GVHD-related mortality with broad-spectrum antibiotic use after allogeneic hematopoietic stem cell transplantation in human patients and mice.

Shono Y, Docampo MD, Peled JU, Perobelli SM, Velardi E, Tsai JJ, Slingerland AE, Smith OM, Young LF, Gupta J, Lieberman SR, Jay HV, Ahr KF, Porosnicu Rodriguez KA, Xu K, Calarfiore M, Poeck H, Caballero S, Devlin SM, Rapaport F, Dudakov JA, Hanash AM, Gyurkocza B, Murphy GF, Gomes C, Liu C, Moss EL, Falconer SB, Bhatt AS, Taur Y, Pamer EG, van den Brink MRM, Jenq RR.

Sci Transl Med. 2016 May 18;8(339):339ra71. doi: 10.1126/scitranslmed.aaf2311.

3.

Piperacillin-tazobactam vs. imipenem-cilastatin as empirical therapy in hematopoietic stem cell transplantation recipients with febrile neutropenia.

Jing Y, Li J, Yuan L, Zhao X, Wang Q, Yu L, Zhou D, Huang W.

Clin Transplant. 2016 Mar;30(3):263-9. doi: 10.1111/ctr.12685. Epub 2016 Feb 2.

PMID:
26701371
4.

Imipenem/cilastatin versus piperacillin/tazobactam plus amikacin for empirical therapy in febrile neutropenic patients: results of the COSTINE study.

Sanz MA, Bermúdez A, Rovira M, Besalduch J, Pascual MJ, Nocea G, Sanz-Rodríguez C; COSTINE Study Group.

Curr Med Res Opin. 2005 May;21(5):645-55.

PMID:
15969864
5.

Imipenem-cilastatin versus piperacillin-tazobactam as monotherapy in febrile neutropenia.

Vural S, Erdem E, Gulec SG, Yildirmak Y, Kebudi R.

Pediatr Int. 2010 Apr;52(2):262-7. doi: 10.1111/j.1442-200X.2009.02952.x. Epub 2009 Sep 7.

PMID:
19744230
6.
7.

Retrospective evaluation of piperacillin-tazobactam, imipenem-cilastatin and meropenem used on surgical floors at a tertiary care hospital in Saudi Arabia.

Youssif E, Aseeri M, Khoshhal S.

J Infect Public Health. 2018 Jul - Aug;11(4):486-490. doi: 10.1016/j.jiph.2017.09.001. Epub 2017 Nov 15.

9.

Piperacillin/tazobactam versus imipenem/cilastatin in the treatment of intra-abdominal infections.

Niinikoski J, Havia T, Alhava E, Pääkkönen M, Miettinen P, Kivilaakso E, Haapiainen R, Matikainen M, Laitinen S.

Surg Gynecol Obstet. 1993 Mar;176(3):255-61.

PMID:
8382381
10.

Prospective randomized comparison of imipenem-cilastatin and piperacillin-tazobactam in nosocomial pneumonia or peritonitis.

Jaccard C, Troillet N, Harbarth S, Zanetti G, Aymon D, Schneider R, Chiolero R, Ricou B, Romand J, Huber O, Ambrosetti P, Praz G, Lew D, Bille J, Glauser MP, Cometta A.

Antimicrob Agents Chemother. 1998 Nov;42(11):2966-72. Erratum in: Antimicrob Agents Chemother 1999 Mar;43(3):726.

12.

Cost efficacy of tazobactam/piperacillin versus imipenem/cilastatin in the treatment of intra-abdominal infection.

Dietrich ES, Schubert B, Ebner W, Daschner F.

Pharmacoeconomics. 2001 Jan;19(1):79-94.

PMID:
11252548
13.

Piperacillin-tazobactam versus imipenem-cilastatin for treatment of intra-abdominal infections.

Brismar B, Malmborg AS, Tunevall G, Wretlind B, Bergman L, Mentzing LO, Nyström PO, Kihlström E, Bäckstrand B, Skau T, et al.

Antimicrob Agents Chemother. 1992 Dec;36(12):2766-73.

14.

Pharmacoeconomics of piperacillin/tazobactam and imipenem/cilastatin in the treatment of patients with intra-abdominal infections.

Jhee SS, Gill MA, Yellin AE, Berne TV, Heseltine PN, Appleman MD.

Clin Ther. 1995 Jan-Feb;17(1):126-35.

PMID:
7758055
15.

[Comparative study of piperacillin/tazobactam versus imipenem/cilastatin in febrile neutropenia (1994-1996)].

Figuera A, Rivero N, Pajuelo F, Font P, Leyra F, de La Cámara R, Arranz R, María Fernández Rañada J.

Med Clin (Barc). 2001 May 5;116(16):610-1. Spanish.

PMID:
11412645
16.

Gut microbiota injury in allogeneic haematopoietic stem cell transplantation.

Shono Y, van den Brink MRM.

Nat Rev Cancer. 2018 May;18(5):283-295. doi: 10.1038/nrc.2018.10. Epub 2018 Feb 16. Review.

PMID:
29449660
17.

Metagenomic analysis of the stool microbiome in patients receiving allogeneic stem cell transplantation: loss of diversity is associated with use of systemic antibiotics and more pronounced in gastrointestinal graft-versus-host disease.

Holler E, Butzhammer P, Schmid K, Hundsrucker C, Koestler J, Peter K, Zhu W, Sporrer D, Hehlgans T, Kreutz M, Holler B, Wolff D, Edinger M, Andreesen R, Levine JE, Ferrara JL, Gessner A, Spang R, Oefner PJ.

Biol Blood Marrow Transplant. 2014 May;20(5):640-5. doi: 10.1016/j.bbmt.2014.01.030. Epub 2014 Jan 31.

18.

A Multicenter Study of Bacterial Blood Stream Infections in Pediatric Allogeneic Hematopoietic Cell Transplantation Recipients: The Role of Acute Gastrointestinal Graft-versus-Host Disease.

Satwani P, Freedman JL, Chaudhury S, Jin Z, Levinson A, Foca MD, Krajewski J, Sahdev I, Talekar MK, Gardenswartz A, Silverman J, Hayes M, Dvorak CC.

Biol Blood Marrow Transplant. 2017 Apr;23(4):642-647. doi: 10.1016/j.bbmt.2017.01.073. Epub 2017 Jan 16.

19.

PD-1 and CTLA-4 up regulation on donor T cells is insufficient to prevent GvHD in allo-HSCT recipients.

Hossain MS, Kunter GM, El-Najjar VF, Jaye DL, Al-Kadhimi Z, Taofeek OK, Li JM, Waller EK.

PLoS One. 2017 Sep 27;12(9):e0184254. doi: 10.1371/journal.pone.0184254. eCollection 2017.

20.

Piperacillin/tazobactam in the treatment of Klebsiella pneumoniae infections in neonates.

Pillay T, Pillay DG, Adhikari M, Sturm AW.

Am J Perinatol. 1998 Jan;15(1):47-51.

PMID:
9475688

Supplemental Content

Support Center